Physician profile
Aaron T Bowman
NPI 1356430227
$5,311.30
in general payments reported to CMS, 2019-2025
55 companies · $549 in 2025
The $549 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $115 · 2021: $600 · 2022: $1,216 · 2023: $735 · 2024: $1,475 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677 · Education: $82.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.70 |
| Education | $82.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $475.16 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $297.97 | 2019-2025 | |
| Incyte Corporation | $297.01 | 2019-2024 | Monjuvi, Pemazyre, Jakafi |
| Merck Sharp & Dohme LLC | $290.54 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $281.57 | 2022-2025 | Enhertu, Lynparza |
| Blueprint Medicines Corporation | $231.37 | 2021-2022 | |
| Daiichi Sankyo INC. | $230.08 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $219.44 | 2022-2023 | |
| Janssen Biotech, INC. | $203.48 | 2019-2025 | Akeega, Erleada, Balversa |
| Spectrum Pharmaceuticals INC. | $181.83 | 2023 | Rolvedon |
| Astellas Pharma US INC | $163.98 | 2019-2025 | Padcev, Xospata |
| Pfizer INC. | $150.59 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $136.50 | 2024 | Onivyde |
| Eisai INC. | $136.03 | 2020-2024 | |
| Glaxosmithkline, LLC. | $134.70 | 2022-2024 | Jemperli, Zejula |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.